Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emergent BioSolutions Inc. (NYSE: EBS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange‑listed pharmaceutical preparation manufacturing company, Emergent submits annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its operations, financial condition and material events.
In its recent Form 8‑K filings, Emergent has reported topics such as quarterly financial and operating results, voluntary prepayment under a term loan facility, contract modifications and options for medical countermeasures, regulatory approvals for manufacturing changes, and changes in board membership. These current reports often incorporate press releases and presentation materials by reference, giving additional detail on product revenues, segment performance and government contract activity.
Filings also confirm that Emergent’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol EBS. Disclosures identify its reportable segments, including Commercial Products and MCM Products, and describe how Services and contracts and grants revenues are presented. Other events filings outline contract modifications with agencies such as the Administration for Strategic Preparedness and Response and BARDA for products including ACAM2000®, CYFENDUS™, BioThrax® and BAT®.
On Stock Titan, investors can review these SEC documents alongside AI‑generated summaries that highlight key points from lengthy filings. Real‑time updates from EDGAR surface new 10‑K and 10‑Q reports as they are filed, while Form 8‑K items flag significant developments in financing, contracts, regulatory approvals and governance. Users can also track how Emergent describes its medical countermeasures portfolio, naloxone products and segment structure over time through its official regulatory language.
Emergent BioSolutions (EBS) executive Michael M. Trova, EVP, Quality & Ethics, and CPL, sold 30,608 shares of common stock at $10.00 on 10/07/2025 pursuant to a Rule 10b5-1(c) trading plan adopted on December 2, 2024. Following the sale, he beneficially owns 144,319 shares.
The filing notes it was submitted late due to an inadvertent administrative error.
Emergent BioSolutions filed a Form 144 reporting a proposed sale of 30,608 common shares with an aggregate market value of
Emergent BioSolutions entered into a new, material agreement with the U.S. government tied to its smallpox vaccine. On September 5, 2025, a contract modification from the Office of the Assistant Secretary for Preparedness and Response exercised Option Year 6 under the existing 10-year ACAM2000® contract. The modification is valued at $56 million and requires Emergent to deliver doses of its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government by December 31, 2025.
The company also referenced that the full text of this modification will be filed with its next quarterly report, and that the base ACAM2000 contract is already on file as a material agreement. In a related move, Emergent issued a press release on September 9, 2025 describing the modification, which is attached as an exhibit to this report for investors seeking additional detail.
Emergent BioSolutions Inc. disclosed a new government order for its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). On August 29, 2025, the company received Modification No. 20 to its existing BARDA AV7909 Contract with the Biomedical Advanced Research and Development Authority, providing for procurement of additional CYFENDUS doses valued at $30.0 million.
The underlying BARDA AV7909 Contract, originally effective September 30, 2016 and amended several times, supports development and procurement of this anthrax vaccine. Emergent also issued a press release on September 2, 2025 describing the modification, and filed the full text of Modification No. 20 and the press release as exhibits.
Kathryn C. Zoon, a director of Emergent BioSolutions, reported the sale of 7,086 shares of Emergent common stock on 08/15/2025 at an exact price of $8.87 per share. After the transaction she beneficially owned 71,799 shares. The filing states the shares were sold under a Rule 10b5-1 trading plan dated May 16, 2025 to satisfy tax obligations arising from RSU vesting on May 22 and May 25, 2025. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Emergent Biosolutions (EBS) reported a Form 144 notice to sell restricted common stock. The filing shows an intended sale of 7,086 shares with an aggregate market value of $62,852.82, representing part of a total 53,351,099 shares outstanding. The proposed approximate sale date is 08/15/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares to be sold were acquired as restricted stock: 6,101 shares on 05/08/2025 and 985 shares on 05/25/2025, with payment recorded on the acquisition dates. The filer reports no securities sold by the same person during the past three months and makes the required representation about material nonpublic information.
Donald W. DeGolyer, a director of Emergent BioSolutions (EBS), sold 7,844 shares of common stock on 08/12/2025 at an exact price of $8.6475 per share to satisfy tax obligations arising from the settlement of vested restricted stock units (RSUs) on 05/22/2025. After this tax-withholding sale the reporting person directly beneficially owns 137,659 shares. The filing lists the transaction code "S" and provides the explanation that the sale was executed solely to satisfy tax withholding related to the RSU settlement.
Emergent Biosolutions (EBS) filed a Form 144 reporting a proposed sale of 7,844 shares of common stock that were acquired as restricted stock from the issuer on 05/08/2025. The filing lists an aggregate market value of $67,830.99 for the shares and shows 53,351,099 shares outstanding for the issuer. The seller reports an approximate date of sale of 08/12/2025 and the transaction is to occur on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The form indicates no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard representation that the signer does not possess undisclosed material adverse information about the issuer.